Literature DB >> 11236049

Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants.

H Holmström1, C Hall, E Thaulow.   

Abstract

UNLABELLED: The main purpose of this study was to investigate whether circulating natriuretic peptides in premature infants reflect the hemodynamic significance of a patent ductus arteriosus (PDA). The study comprises 120 examinations in 55 premature infants with a mean gestational age of 27.2 wk and a mean birthweight of 933 g. Based on clinical and echocardiographic findings, the hemodynamic influence of ductal shunting was classified as small, moderate or large. Blood samples for N-terminal proatrial natriuretic peptide (Nt-proANP) and brain natriuretic peptide (BNP) were analysed after completion of the clinical part of the study. Linear regression indicated a very strong association between Nt-proANP and BNP (adjusted R = 0.89). The mean levels of Nt-proANP and BNP increased with the size of the shunt through a PDA, and peptide values followed hemodynamic alterations. The size of PDA accounted for 50% and 47% of the total variation in the plasma values of Nt-proANP and BNP, respectively. In detecting an echocardiographically significant PDA, the area under a ROC curve was 0.94 for Nt-proANP and 0.90 for BNP.
CONCLUSION: The magnitude of shunting through a PDA is the main determinant of plasma levels of natriuretic peptides in premature infants. Nt-proANP and BNP seem to have the same pattern of secretion. Our findings indicate that measurements of natriuretic peptides may provide clinically relevant information in the hemodynamic assessment of premature infants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236049     DOI: 10.1080/080352501300049406

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

1.  N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool?

Authors:  Cathy Hammerman; Irena Shchors; Michael S Schimmel; Ruben Bromiker; Michael Kaplan; Amiram Nir
Journal:  Pediatr Cardiol       Date:  2009-10-27       Impact factor: 1.655

2.  The relationship between BNP, NTproBNP and echocardiographic measurements of systemic blood flow in very preterm infants.

Authors:  K König; K J Guy; G Walsh; S M Drew; A Watkins; C P Barfield
Journal:  J Perinatol       Date:  2014-02-06       Impact factor: 2.521

Review 3.  N-terminal pro-brain natriuretic peptide level as a screening tool for cardiac involvement in paediatric diseases of extracardiac origin.

Authors:  Eva Welisch; Kambiz Norozi; Ralf Rauch
Journal:  Clin Res Cardiol       Date:  2011-04-14       Impact factor: 5.460

4.  Neonate with vein of Galen malformation and heart failure: serial changes in plasma B-type natriuretic peptide following endovascular embolization.

Authors:  L H Tan; B A Johnson; M E Mawad; A C Chang
Journal:  Pediatr Cardiol       Date:  2006-02-20       Impact factor: 1.655

5.  B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants.

Authors:  Joon Sik Kim; Eun Jung Shim
Journal:  Korean Circ J       Date:  2012-03-26       Impact factor: 3.243

6.  Normal values of B type natriuretic peptide in infants, children, and adolescents.

Authors:  A Koch; H Singer
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

7.  Aminoterminal Pro B-Type Natriuretic Peptide (NT-proBNP) Levels for Monitoring Interventions in Paediatric Cardiac Patients with Stenotic Lesions.

Authors:  Eva Welisch; Knut Kleesiek; Nikolaus Haas; Kambiz Norozi; Ralf Rauch; Guido Filler
Journal:  Int J Pediatr       Date:  2010-02-24

Review 8.  Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?

Authors:  Afif El-Khuffash; Eleanor J Molloy
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-07       Impact factor: 5.747

9.  Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease?

Authors:  Seyma Kayali; Ilker Ertugrul; Tamer Yoldas; Ozkan Kaya; Senem Ozgür; Utku A Orün; Selmin Karademir
Journal:  Pediatr Cardiol       Date:  2018-01-16       Impact factor: 1.655

10.  The Use of N-Terminal-Pro-BNP in Preterm Infants.

Authors:  Afif El-Khuffash; Eleanor Molloy
Journal:  Int J Pediatr       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.